Estrella Immunopharma, Inc. (ESLA) Stock Analysis & Investment Frameworks
Estrella Immunopharma, Inc. (ESLA) stock analysis on Invetso. Review Estrella Immunopharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Estrella Immunopharma, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Estrella Immunopharma, Inc. Key Financial Metrics
- Market Cap: $42.85M
- Revenue: $N/A
- ROE: 121.72%
- ROIC: 131.75%
- Dividend Yield: N/A
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Estrella Immunopharma, Inc. Investment Frameworks
Invetso analyzes Estrella Immunopharma, Inc. (ESLA) across the following frameworks:
- Estrella Immunopharma, Inc. 10Y Growth Potential
- Estrella Immunopharma, Inc. Scenario Analysis
- Estrella Immunopharma, Inc. Risks & Opportunities
- Estrella Immunopharma, Inc. Economic Moat
- Estrella Immunopharma, Inc. Business Model
- Estrella Immunopharma, Inc. Management
- Estrella Immunopharma, Inc. SWOT Analysis
- Estrella Immunopharma, Inc. Porter's 5 Forces
- Estrella Immunopharma, Inc. PESTLE Analysis
- Estrella Immunopharma, Inc. ESG Analysis